Clinical Trial Update: Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 follow-up study reporting long-term outcomes over 11 years for patients enrolled in the BENEFIT trial with a first demyelinating event suggestive of mul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Betaseron (Interferon beta-1b)

Snippet

Sponsor: Bayer | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED